©DANIEL ROUSSELOT/Sanofi

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

Originally published on Sanofi.com.

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

*Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine

PARIS – February 18, 2020 – Sanofi Pasteur, the vaccines global business unit of Sanofi, will leverage previous development work for a SARS vaccine which may unlock a fast path forward for developing a COVID-19 vaccine. Sanofi will collaborate with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response, expanding the company’s long-standing partnership with BARDA.

COVID-19 belongs to a family of coronaviruses that can cause respiratory disease. In late 2002, the SARS (severe acute respiratory syndrome) coronavirus emerged and then largely disappeared by 2004. Sanofi plans to further investigate an advanced pre-clinical SARS vaccine candidate that could protect against COVID-19.

“Addressing a global health threat such as this newest coronavirus is going to take a collaborative effort, which is why we are working with BARDA to quickly advance a potential vaccine candidate,” said David Loew, Global Head of Vaccines at Sanofi. “While we are lending our expertise where possible, we believe the collaboration with BARDA may provide the most meaningful results in protecting the public from this latest outbreak.”

Sanofi to utilize innovative recombinant technology platform

Sanofi will use its recombinant DNA platform to produce a 2019 novel coronavirus vaccine candidate.  The recombinant technology produces an exact genetic match to proteins found on the surface of the virus. The DNA sequence encoding this antigen will be combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product, and used to rapidly produce large quantities of the coronavirus antigen which will be formulated to stimulate the immune system to protect against the virus.

        “Emerging global health threats like the 2019 novel coronavirus require a rapid response,” said BARDA Director Rick A. Bright, Ph.D.  “By expanding our partnership               with Sanofi Pasteur and leveraging a licensed recombinant vaccine platform, we hope to speed development of a vaccine candidate to protect against a new virus.”

Sanofi uniquely positioned in search for a coronavirus vaccine

In non-clinical studies, the SARS vaccine candidate was immunogenic and afforded partial protection as assessed in animal challenge models. This development work by Protein Sciences (acquired by Sanofi in 2017) provides a head start in expediting a COVID-19 vaccine. Additionally, since there is a licensed vaccine based on this platform this will allow for research and materials to be produced relatively quickly for clinical testing. Sanofi’s platform also has the potential to manufacture large quantities of the vaccine candidate.

Sanofi’s long-standing commitment to protecting public health

This agreement with BARDA marks another milestone in Sanofi’s ongoing contributions to help fight public health threats.  Sanofi continues to actively explore potential opportunities where the company’s deep vaccine experience and innovative technologies may contribute to addressing the coronavirus public health situation, including sharing Sanofi’s vaccine research and development experience with the Coalition for Epidemic Preparedness Innovations.

In December 2019, Sanofi also entered into an agreement with BARDA to establish state of the art facilities in the U.S. for the sustainable production of an adjuvanted recombinant vaccine for use in the event of an influenza pandemic and based on the same technology platform that will be used for the COVID-19 program.

Latest News

Atatiana Jefferson

Wrongful Death Lawsuit Filed in Police Shooting of Atatiana Jefferson; Drug Industry Announces Diversity Guidelines in Development of New Medications; and More

Wrongful death lawsuit filed in the fatal shooting of Atatiana Jefferson by police. Family members of Atatiana Jefferson, a 28-year-old Black woman who was fatally shot by police through a window in her own home, have filed a wrongful death lawsuit against the city of Fort Worth, Texas and the…

Southern Company: Georgia Natural Gas Opens 10th Annual TrueBlue Community Awards Call for Entries

Originally published on southerncompany.com. Honor recognizes nonprofits supporting Georgia during COVID-19 and distributes grants to sustain continued efforts Georgia Natural Gas (GNG), Georgia’s leading natural gas provider, announces the call for entries for the 10th Annual TrueBlue Community Awards. This year, the awards will recognize hardworking Georgia nonprofits for their service providing COVID-19 relief…

Cori Bush

Multiple Congressmen ‘Accidentally’ Called Cori Bush, Missouri’s New Representative, ‘Breonna’; American Medical Association Classifies Racism as a Threat to Public Health; and More

Multiple congressmen “accidentally” called Missouri’s new representative Cori Bush  “Breonna” during Capitol event. Congresswoman-elect Cori Bush said she was stunned and hurt on the evening of Nov. 16, after a number of different Republicans called her “Breonna” during a new member orientation at the Capitol in Washington, D.C. Bush, who…

transgender, election

Meet 6 Transgender and Gender-Nonbinary Politicians Who Broke Ground in 2020

Despite the fraught nature of the 2020 presidential election results, victories at state levels put at least six transgender and nonbinary individuals in legislative positions. These small but significant gains for transgender visibility in politics came just before Transgender Awareness Week, which celebrates transgender people from Nov. 13–19 before Transgender…

Roger Ferguson to Retire as President and CEO of TIAA

Originally published on tiaa.org. TIAA, a leading provider of secure retirements and outcome-focused investment solutions to millions of people and thousands of institutions, said Roger W. Ferguson, Jr., intends to retire as President and CEO on March 31, 2021. The company’s Board and Mr. Ferguson believe it is an appropriate…

Justice Samuel Alito

Justice Samuel Alito Delivers Series of Highly Alarming Partisan Remarks; Racism Impairs Brain Performance, and More

Supreme Court Justice Samuel Alito delivers an alarming series of homophobic, partisan remarks. Supreme Court Justice Samuel Alito rarely makes public appearances, but when he does he apparently wants to make them count, being as irksome and controversial as possible — and completely disregarding the usual ethics required of judges…

Hershey: Leading With Empathy and Connection

Originally published on thehersheycompany.com by Katrina J. Briddell Manager, Global Sustainability & Social Impact There’s no denying: it’s been a tough year for everyone around the world. Here in the U.S., we’ve faced an unrelenting pandemic, mass movements for racial justice, raging wildfires, devastating hurricanes, and an election cycle that…